Exelixis taps into cancer antibody discoverer out of Sweden
Exelixis is doling out $25 million to snag rights to choose three targets found by BioInvent.
The California cancer drugmaker is linking arms with the Swedish biotech — both founded in the mid 90s — to expand its suite of antibodies for immuno-oncology. BioInvent will offer up its cancer immunology and antibody biology chops and Exelixis will bring its antibody-drug conjugate tech to the table.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.